Stem Cell Injection into the Meibomian Glands Should Help the Glands Regrow: What to do About Chronic Neurotropic Dry Eye Disease from Lasik (CiNDryELa)

Research into the ability of stem cells to regenerate the Meibomian Gland cells is non-existent currently. However, there are studies, such as the one below, that indicates Stem Cell treatment topically (that means as drops) helps improve dry eye signs (at least in rats).

One of the best things about injecting stem cells into the Meibomian Glands is that we have an objective way to see if it works or not: Meibography or LipiScan.

I had posted before about the before and after photos of a patient who had IPL: Intense Pulse Light
http://eyedoc2020.blogspot.com/2016/11/ipl-intense-pulse-light-before-and.html?q=2+patients



Left Lower Lid Before IPL on the left photo.          After IPL of left lower lid on right photo.

Though there is a slight magnification issue on the photos, and the eyelid is pulled down more in the before photo (which can make glands looks smaller), it does look like some of the glands have more oil, especially the first 4 glands: they look like they have regenerated. The patient's symptoms have also improved and she has significantly less staining on the cornea.



The study below used a rat's bone marrow to obtain stem cells. I suspect if they had used the rat's fat, they might have had even better results.

I suspect fat derived stem cells may be an alternative option to autolgous serum and may help those patients who do not improve on autologous serum alone: many have Chronic Neurotropic Dry Eye Disease from Lasik (CiNDryELa). Some of the these patients who have had no benefit with Autologous Serum have underlying autoimmune disease.

Sandra Lora Crermers, MD, FACS

Stem Cells International
Volume 2014 (2014), Article ID 250230, 9 pages
http://dx.doi.org/10.1155/2014/250230

Research Article

Efficacy of Topical Mesenchymal Stem Cell Therapy in the Treatment of Experimental Dry Eye Syndrome Model

Emrullah Beyazyıldız,1 Ferda Alpaslan Pınarlı,2 Özlem Beyazyıldız,1 Emine Rümeysa Hekimoğlu,3 Uğur Acar,4 Muhammed Necati Demir,5 Aynur Albayrak,6 Figen Kaymaz,7 Güngör Sobacı,8 and Tuncay Delibaşı9

Purpose. The current study was set out to address the therapeutic efficacy of topically applied mesenchymal stem cells (MSCs) on dry eye syndrome (DES) induced by benzalkonium chloride (BAC) in rats. Methods. Rats were divided into two groups just after establishment of DES. Eye drops containing either bromodeoxyuridine labeled MSCs () or phosphate buffer solution () were topically applied once daily for one week. Schirmer test, break-up time score, ocular surface evaluation tests, and corneal inflammatory index scoring tests were applied to all rats at baseline and after treatment. All rats were sacrificed after one week for histological and electron microscopic analysis. Results. Mean aqueous tear volume and tear film stability were significantly increased in rats treated with MSCs (). Infiltration of bromodeoxyuridine labeled MSCs into the meibomian glands and conjunctival epithelium was observed in MSCs treated rats. Increased number of secretory granules and number of goblet cells were observed in MSCs treated rats. Conclusion. Topical application of MSCs could be a safe and effective method for the treatment of DES and could potentially be used for further clinical research studies.